The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response
Hepatitis C Virus (HCV) infection is a major health concern worldwide. The presence of both HCV viral RNA and NS5A proteins in peripheral blood mononuclear cells (PBMCs) indicate the efficacy of the treatment during sustained virological response (SVR) and end of treatment response (ETR). The main o...
Gespeichert in:
| Veröffentlicht in: | Viral immunology 2017-10, Vol.30 (8), p.568-575 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 575 |
|---|---|
| container_issue | 8 |
| container_start_page | 568 |
| container_title | Viral immunology |
| container_volume | 30 |
| creator | Mehmood, Azhar Asad, Muhammad Javaid Ovais, Muhammad Zaman, Nasib Aziz, Hafsa Irfan, Javaid Ahmad, Irshad Raza, Abida |
| description | Hepatitis C Virus (HCV) infection is a major health concern worldwide. The presence of both HCV viral RNA and NS5A proteins in peripheral blood mononuclear cells (PBMCs) indicate the efficacy of the treatment during sustained virological response (SVR) and end of treatment response (ETR). The main objective of this study was to detect the absence or presence of HCV RNA and NS5A proteins in PBMCs. Blood samples were taken from selected patients (Islamabad, Pakistan) before treatment, at ETR, and during SVR. Two hundred HCV responders to pegylated IFN-
α
-2a plus ribavirin were selected. HCV RNA was extracted from the patients to determine the viral load by reverse transcription (RT)-polymerase chain reaction before treatment. Out of 200 patients, 152 (76%) and 48 (24%) achieved positive and negative ETR, respectively. Among ETR patients, 134 (88.2%) showed SVR, whereas 18 (11.8%) displayed relapse. The male to female ratio was 92:108 with mean age of 37.4 years. Among 152 ETR-positive patients, 29 (19%) patients' PBMCs were positive for HCV RNA and 27 (17.8%) were positive for NS55A proteins. Patients having HCV RNA in PBMCs showed higher relapse frequency compared with patients lacking it. Similarly, patients having NS5A protein showed significantly higher relapse frequency compared with patients lacking it. All PBMC-positive samples were of genotype 3a. In addition, patients with positive NS5A in their PBMCs showed greater risk of relapse compared with patients having HCV RNA. We conclude that the absence of both viral HCV and proteins can be used as an indicator for diagnosis of SVR in the future. |
| doi_str_mv | 10.1089/vim.2017.0030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1949150829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1949150829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-b4ce1636fa456e6ac5f92af9f91d98b7e92768b867326f296d44da1b385276fd3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EokvhyBWNxDmLv-LYx2UFbaVSqnbpNXKScevKay92gsQP6P8m0RauSCONNPPMO9JDyHtG14xq8-mX3685Zc2aUkFfkBWr66bSplEvyYpqzSvNZX1C3pTySCnVSovX5IRr3Qgq5Io87R4QNl3B2CMkB-fbO7i52oCNA1zd1hu4zmlEH2Gua8z-8IDZBvgcUhrgW4opTn1Am2GLIRS4KGCXk_uYyuh72KUUwKUMt1MZrY84wJ3PKaR7388xN1gOKRZ8S145Gwq-e-6n5MfXL7vteXX5_exiu7mseknlWHWyR6aEclbWCpXta2e4dcYZNhjdNWh4o3SnVSO4ctyoQcrBsk7oel64QZySj8fcQ04_Jyxj-5imHOeXLTPSsJpqbmaqOlJ9TqVkdO0h-73Nv1tG20V6O0tvF-ntIn3mPzynTt0eh3_0X8szII7AMrYxBo8d5vE_sX8AEh2NxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1949150829</pqid></control><display><type>article</type><title>The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Mehmood, Azhar ; Asad, Muhammad Javaid ; Ovais, Muhammad ; Zaman, Nasib ; Aziz, Hafsa ; Irfan, Javaid ; Ahmad, Irshad ; Raza, Abida</creator><creatorcontrib>Mehmood, Azhar ; Asad, Muhammad Javaid ; Ovais, Muhammad ; Zaman, Nasib ; Aziz, Hafsa ; Irfan, Javaid ; Ahmad, Irshad ; Raza, Abida</creatorcontrib><description>Hepatitis C Virus (HCV) infection is a major health concern worldwide. The presence of both HCV viral RNA and NS5A proteins in peripheral blood mononuclear cells (PBMCs) indicate the efficacy of the treatment during sustained virological response (SVR) and end of treatment response (ETR). The main objective of this study was to detect the absence or presence of HCV RNA and NS5A proteins in PBMCs. Blood samples were taken from selected patients (Islamabad, Pakistan) before treatment, at ETR, and during SVR. Two hundred HCV responders to pegylated IFN-
α
-2a plus ribavirin were selected. HCV RNA was extracted from the patients to determine the viral load by reverse transcription (RT)-polymerase chain reaction before treatment. Out of 200 patients, 152 (76%) and 48 (24%) achieved positive and negative ETR, respectively. Among ETR patients, 134 (88.2%) showed SVR, whereas 18 (11.8%) displayed relapse. The male to female ratio was 92:108 with mean age of 37.4 years. Among 152 ETR-positive patients, 29 (19%) patients' PBMCs were positive for HCV RNA and 27 (17.8%) were positive for NS55A proteins. Patients having HCV RNA in PBMCs showed higher relapse frequency compared with patients lacking it. Similarly, patients having NS5A protein showed significantly higher relapse frequency compared with patients lacking it. All PBMC-positive samples were of genotype 3a. In addition, patients with positive NS5A in their PBMCs showed greater risk of relapse compared with patients having HCV RNA. We conclude that the absence of both viral HCV and proteins can be used as an indicator for diagnosis of SVR in the future.</description><identifier>ISSN: 0882-8245</identifier><identifier>EISSN: 1557-8976</identifier><identifier>DOI: 10.1089/vim.2017.0030</identifier><identifier>PMID: 28873034</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Biochemistry ; Female ; Genomes ; Genotype ; Genotype & phenotype ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatitis C - virology ; Hepatology ; HIV ; Human immunodeficiency virus ; Humans ; Infections ; Interferon ; Interferon alpha-2 ; Interferon-alpha - therapeutic use ; Leukocytes (mononuclear) ; Leukocytes, Mononuclear - virology ; Liver ; Male ; Middle Aged ; NS5A protein ; Nuclear medicine ; Oncology ; Original Articles ; Pakistan ; Patients ; Peripheral blood mononuclear cells ; Polymerase chain reaction ; Prognosis ; Proteins ; Radiation therapy ; Recombinant Proteins - therapeutic use ; Recurrence ; Reverse transcription ; Ribavirin ; Ribavirin - therapeutic use ; Ribonucleic acid ; RNA ; RNA, Viral - blood ; Substance abuse treatment ; Treatment Outcome ; Viral infections ; Viral Load ; Viral Nonstructural Proteins - blood ; Viruses</subject><ispartof>Viral immunology, 2017-10, Vol.30 (8), p.568-575</ispartof><rights>2017, Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2017, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-b4ce1636fa456e6ac5f92af9f91d98b7e92768b867326f296d44da1b385276fd3</citedby><cites>FETCH-LOGICAL-c404t-b4ce1636fa456e6ac5f92af9f91d98b7e92768b867326f296d44da1b385276fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28873034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mehmood, Azhar</creatorcontrib><creatorcontrib>Asad, Muhammad Javaid</creatorcontrib><creatorcontrib>Ovais, Muhammad</creatorcontrib><creatorcontrib>Zaman, Nasib</creatorcontrib><creatorcontrib>Aziz, Hafsa</creatorcontrib><creatorcontrib>Irfan, Javaid</creatorcontrib><creatorcontrib>Ahmad, Irshad</creatorcontrib><creatorcontrib>Raza, Abida</creatorcontrib><title>The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response</title><title>Viral immunology</title><addtitle>Viral Immunol</addtitle><description>Hepatitis C Virus (HCV) infection is a major health concern worldwide. The presence of both HCV viral RNA and NS5A proteins in peripheral blood mononuclear cells (PBMCs) indicate the efficacy of the treatment during sustained virological response (SVR) and end of treatment response (ETR). The main objective of this study was to detect the absence or presence of HCV RNA and NS5A proteins in PBMCs. Blood samples were taken from selected patients (Islamabad, Pakistan) before treatment, at ETR, and during SVR. Two hundred HCV responders to pegylated IFN-
α
-2a plus ribavirin were selected. HCV RNA was extracted from the patients to determine the viral load by reverse transcription (RT)-polymerase chain reaction before treatment. Out of 200 patients, 152 (76%) and 48 (24%) achieved positive and negative ETR, respectively. Among ETR patients, 134 (88.2%) showed SVR, whereas 18 (11.8%) displayed relapse. The male to female ratio was 92:108 with mean age of 37.4 years. Among 152 ETR-positive patients, 29 (19%) patients' PBMCs were positive for HCV RNA and 27 (17.8%) were positive for NS55A proteins. Patients having HCV RNA in PBMCs showed higher relapse frequency compared with patients lacking it. Similarly, patients having NS5A protein showed significantly higher relapse frequency compared with patients lacking it. All PBMC-positive samples were of genotype 3a. In addition, patients with positive NS5A in their PBMCs showed greater risk of relapse compared with patients having HCV RNA. We conclude that the absence of both viral HCV and proteins can be used as an indicator for diagnosis of SVR in the future.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Biochemistry</subject><subject>Female</subject><subject>Genomes</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - virology</subject><subject>Hepatology</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Interferon</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Leukocytes (mononuclear)</subject><subject>Leukocytes, Mononuclear - virology</subject><subject>Liver</subject><subject>Male</subject><subject>Middle Aged</subject><subject>NS5A protein</subject><subject>Nuclear medicine</subject><subject>Oncology</subject><subject>Original Articles</subject><subject>Pakistan</subject><subject>Patients</subject><subject>Peripheral blood mononuclear cells</subject><subject>Polymerase chain reaction</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Recurrence</subject><subject>Reverse transcription</subject><subject>Ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Viral - blood</subject><subject>Substance abuse treatment</subject><subject>Treatment Outcome</subject><subject>Viral infections</subject><subject>Viral Load</subject><subject>Viral Nonstructural Proteins - blood</subject><subject>Viruses</subject><issn>0882-8245</issn><issn>1557-8976</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkE1v1DAQhi0EokvhyBWNxDmLv-LYx2UFbaVSqnbpNXKScevKay92gsQP6P8m0RauSCONNPPMO9JDyHtG14xq8-mX3685Zc2aUkFfkBWr66bSplEvyYpqzSvNZX1C3pTySCnVSovX5IRr3Qgq5Io87R4QNl3B2CMkB-fbO7i52oCNA1zd1hu4zmlEH2Gua8z-8IDZBvgcUhrgW4opTn1Am2GLIRS4KGCXk_uYyuh72KUUwKUMt1MZrY84wJ3PKaR7388xN1gOKRZ8S145Gwq-e-6n5MfXL7vteXX5_exiu7mseknlWHWyR6aEclbWCpXta2e4dcYZNhjdNWh4o3SnVSO4ctyoQcrBsk7oel64QZySj8fcQ04_Jyxj-5imHOeXLTPSsJpqbmaqOlJ9TqVkdO0h-73Nv1tG20V6O0tvF-ntIn3mPzynTt0eh3_0X8szII7AMrYxBo8d5vE_sX8AEh2NxQ</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Mehmood, Azhar</creator><creator>Asad, Muhammad Javaid</creator><creator>Ovais, Muhammad</creator><creator>Zaman, Nasib</creator><creator>Aziz, Hafsa</creator><creator>Irfan, Javaid</creator><creator>Ahmad, Irshad</creator><creator>Raza, Abida</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20171001</creationdate><title>The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response</title><author>Mehmood, Azhar ; Asad, Muhammad Javaid ; Ovais, Muhammad ; Zaman, Nasib ; Aziz, Hafsa ; Irfan, Javaid ; Ahmad, Irshad ; Raza, Abida</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-b4ce1636fa456e6ac5f92af9f91d98b7e92768b867326f296d44da1b385276fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Biochemistry</topic><topic>Female</topic><topic>Genomes</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - virology</topic><topic>Hepatology</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Interferon</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Leukocytes (mononuclear)</topic><topic>Leukocytes, Mononuclear - virology</topic><topic>Liver</topic><topic>Male</topic><topic>Middle Aged</topic><topic>NS5A protein</topic><topic>Nuclear medicine</topic><topic>Oncology</topic><topic>Original Articles</topic><topic>Pakistan</topic><topic>Patients</topic><topic>Peripheral blood mononuclear cells</topic><topic>Polymerase chain reaction</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Recurrence</topic><topic>Reverse transcription</topic><topic>Ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Viral - blood</topic><topic>Substance abuse treatment</topic><topic>Treatment Outcome</topic><topic>Viral infections</topic><topic>Viral Load</topic><topic>Viral Nonstructural Proteins - blood</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mehmood, Azhar</creatorcontrib><creatorcontrib>Asad, Muhammad Javaid</creatorcontrib><creatorcontrib>Ovais, Muhammad</creatorcontrib><creatorcontrib>Zaman, Nasib</creatorcontrib><creatorcontrib>Aziz, Hafsa</creatorcontrib><creatorcontrib>Irfan, Javaid</creatorcontrib><creatorcontrib>Ahmad, Irshad</creatorcontrib><creatorcontrib>Raza, Abida</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Viral immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mehmood, Azhar</au><au>Asad, Muhammad Javaid</au><au>Ovais, Muhammad</au><au>Zaman, Nasib</au><au>Aziz, Hafsa</au><au>Irfan, Javaid</au><au>Ahmad, Irshad</au><au>Raza, Abida</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response</atitle><jtitle>Viral immunology</jtitle><addtitle>Viral Immunol</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>30</volume><issue>8</issue><spage>568</spage><epage>575</epage><pages>568-575</pages><issn>0882-8245</issn><eissn>1557-8976</eissn><abstract>Hepatitis C Virus (HCV) infection is a major health concern worldwide. The presence of both HCV viral RNA and NS5A proteins in peripheral blood mononuclear cells (PBMCs) indicate the efficacy of the treatment during sustained virological response (SVR) and end of treatment response (ETR). The main objective of this study was to detect the absence or presence of HCV RNA and NS5A proteins in PBMCs. Blood samples were taken from selected patients (Islamabad, Pakistan) before treatment, at ETR, and during SVR. Two hundred HCV responders to pegylated IFN-
α
-2a plus ribavirin were selected. HCV RNA was extracted from the patients to determine the viral load by reverse transcription (RT)-polymerase chain reaction before treatment. Out of 200 patients, 152 (76%) and 48 (24%) achieved positive and negative ETR, respectively. Among ETR patients, 134 (88.2%) showed SVR, whereas 18 (11.8%) displayed relapse. The male to female ratio was 92:108 with mean age of 37.4 years. Among 152 ETR-positive patients, 29 (19%) patients' PBMCs were positive for HCV RNA and 27 (17.8%) were positive for NS55A proteins. Patients having HCV RNA in PBMCs showed higher relapse frequency compared with patients lacking it. Similarly, patients having NS5A protein showed significantly higher relapse frequency compared with patients lacking it. All PBMC-positive samples were of genotype 3a. In addition, patients with positive NS5A in their PBMCs showed greater risk of relapse compared with patients having HCV RNA. We conclude that the absence of both viral HCV and proteins can be used as an indicator for diagnosis of SVR in the future.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>28873034</pmid><doi>10.1089/vim.2017.0030</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0882-8245 |
| ispartof | Viral immunology, 2017-10, Vol.30 (8), p.568-575 |
| issn | 0882-8245 1557-8976 |
| language | eng |
| recordid | cdi_proquest_journals_1949150829 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Antiviral Agents - therapeutic use Antiviral drugs Biochemistry Female Genomes Genotype Genotype & phenotype Hepacivirus - drug effects Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - virology Hepatology HIV Human immunodeficiency virus Humans Infections Interferon Interferon alpha-2 Interferon-alpha - therapeutic use Leukocytes (mononuclear) Leukocytes, Mononuclear - virology Liver Male Middle Aged NS5A protein Nuclear medicine Oncology Original Articles Pakistan Patients Peripheral blood mononuclear cells Polymerase chain reaction Prognosis Proteins Radiation therapy Recombinant Proteins - therapeutic use Recurrence Reverse transcription Ribavirin Ribavirin - therapeutic use Ribonucleic acid RNA RNA, Viral - blood Substance abuse treatment Treatment Outcome Viral infections Viral Load Viral Nonstructural Proteins - blood Viruses |
| title | The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A46%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Absence%20of%20HCV%20RNA%20and%20NS5A%20Protein%20in%20Peripheral%20Blood%20Mononuclear%20Cells%20Is%20a%20Prognostic%20Tool%20for%20Sustained%20Virological%20Response&rft.jtitle=Viral%20immunology&rft.au=Mehmood,%20Azhar&rft.date=2017-10-01&rft.volume=30&rft.issue=8&rft.spage=568&rft.epage=575&rft.pages=568-575&rft.issn=0882-8245&rft.eissn=1557-8976&rft_id=info:doi/10.1089/vim.2017.0030&rft_dat=%3Cproquest_cross%3E1949150829%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1949150829&rft_id=info:pmid/28873034&rfr_iscdi=true |